The need for alternatives to animal use in pyrogen testing has been driven by the Three Rs concept. This has resulted in the inclusion of the monocyte activation test (MAT) in the European Pharmacopoeia, 2010. However, some technical and regulatory obstacles must be overcome to ensure the effective implementation of the MAT by the industry, especially for the testing of biological products. The yellow fever (YF) vaccine (17DD-YFV) was chosen for evaluation in this study, in view of: a) the 2016–2018 outbreak of YF in Brazil; b) the increase in demand for 17DD-YFV doses; c) the complex production process with live attenuated virus; d) the presence of possible test interference factors, such as residual process components (e.g. ovalbumin); and e) the need for the investigation of other pyrogens that are not detectable by the methods prescribed in the YF vaccine monograph. The product-specific testing was carried out by using cryopreserved and fresh whole blood, and IL-6 and IL-1β levels were used as the marker readouts. After assessing the applicability of the MAT on a 1:10 dilution of 17DD-YFV, endotoxin and non-endotoxin pyrogens were quantified in spiked batches, by using the lipopolysaccharide and lipoteichoic acid standards, respectively. The quantitative analysis demonstrated the correlation between the MAT and the Limulus amoebocyte lysate (LAL) assays, with respect to the limits of endotoxin recovery in spiked batches and the detection of no pyrogenic contamination in commercial batches of 17DD-YFV. The data demonstrated the applicability of the MAT for 17DD-YFV pyrogen testing, and as an alternative method that can contribute to biological quality control studies.
ThomasR.E., LorenzettiD.L., SpraginsW., JacksonD., & WilliamsonT. (2012). The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: Systematic review. American Journal of Tropical Medicine & Hygiene86, 359–372.
7.
Anon., (2010). Vacina Febre Amarela Atenuada Endotoxina bacteriana (5.5.2.2). In Farmacopeia Brasileira, 5a Edição, Parte 2, p. 1364. São Paulo, Brasil: Editora Atheneu.
8.
Anon., (2017). Yellow fever vaccine (live). In The European Pharmacopoeia, 9th Edition, Monograph 0537. Strasbourg, France: European Pharmacopoeia (Ph. Eur.) Commission.
PonteC.F. (2003). Vaccination, quality control, and vaccine production in Brazil since 1960. História, Ciências, Saúde-Manguinhos10, 619–653.
11.
PagliusiS., LeiteL.C., DatlaM., MakhoanaM., GaoY., SuhardonofM., JadhavgS., HarshavardhanhG.V., & HommaiA. (2013). Developing countries vaccine manufacturers network: Doing good by making high-quality vaccines affordable for all. Vaccine, 31S, B176–B183.
12.
Anon., (2010). Monocyte Activation Test. In The European Pharmacopoeia, 7th Edition, Chapter 2.6.30. Strasbourg, France: European Pharmacopoeia (Ph. Eur.) Commission.
13.
HartungT. (2015). The human whole blood pyrogen test — Lessons learned in twenty years. ALTEX32, 79–100.
ICCVAM (2008). Introduction and rationale for the proposed use of in vitro pyrogen test methods. In ICCVAM In Vitro Pyrogenicity BRD, Section 1, 10 pp. Durham, NC, USA: ICCVAM. Available at: https://ntp.niehs.nih.gov/iccvam/docs/pyrogen/brd/1-intro.pdf (Accessed 25.01.18).
16.
KnightP.A., & LuckenR.N. (1977). Studies on the toxicity of a variety of human vaccines as measured by laboratory tests. Developments in Biological Standardisation34, 181–187.
17.
TsaiC.M., FraschC.E., RiveraE., & HochsteinH.D. (1989). Measurements of lipopolysaccharide (endotoxin) in meningococcal protein and polysaccharide preparations for vaccine usage. Journal of Biological Standardisation17, 249–258.
18.
van der LeyP., & van den DobbelsteenG. (2011). Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants. Human Vaccines7, 886–890.
19.
NyergesG., & JaszovszkyI. (1981). Reliability of the rabbit pyrogen test and of the limulus test in predicting the pyrogenicity of vaccines in man. Acta Microbiologica Academiae Scientiarum Hungaricae28, 235–243.
20.
ParkC.Y., JungS.H., BakJ.P., LeeS.S., & RheD.K. (2005). Comparison of the rabbit pyrogen test and Limulus amoebocyte lysate (LAL) assay for endotoxin in hepatitis B vaccines and the effect of aluminum hydroxide. Biologicals33, 145–151.
21.
CarlinG., & ViitanenE. (2003). In vitro pyrogenicity of a multivalent vaccine: Infanrix. Pharmeuropa15, 418–423.
22.
SolatiS., AardenL., ZeerlederS., & WoutersD. (2015). An improved monocyte activation test using cryopreserved pooled human mononuclear cells. Innate Immunology21, 677–684.
23.
SchindlerS., SpreitzerI., LöschnerB., HoffmannS., HennesK., HalderM., BrüggerP., FreyE., HartungT., & MontagT. (2006). International validation of pyrogen tests based on cryopreserved human primary blood cells. Journal of Immunological Methods316, 42–51.
24.
GimenesI., CaldeiraC., MouraW.C., PresgraveO.A.F., & Villas BoasM.H.S. (2015). Assessment of pyrogenic response of lipoteichoic acid by the monocyte activation test and the rabbit pyrogen test. Regulatory Toxicology & Pharmacology73, 356–360.
25.
HasiwaN., DaneshianM., BrueggerP., FennrichS., HochadelA., HoffmannS., Rivera-MarianiF.E., RockelC., SchindlerS., SpreitzerI., StoppelkampS., VysyarajuK., & HartungT. (2013). Evidence for the detection of non-endotoxin pyrogens by the whole blood monocyte activation test. ALTEX30, 169–208.
26.
RussellW.M.S., & BurchR.L. (1959). The Principles of Humane Experimental Technique, 238 pp. London, UK: Methuen.
27.
CusslerK., HalderM., & HendriksenC. (2002). Future activities: ECVAM and the quality control of biologicals. ATLA30, Suppl. 2, 225–226.
28.
Anon., (2008). EU Guidelines to Good Manufacturing Practice, Medicinal Products for Human and Veterinary Use. Annex 1: Manufacture of Sterile Medicinal Products, 16 pp. Brussels, Belgium: European Commission. Available at: http://academy.gmp-compliance.org/guidemgr/files/ANNEX%2001%5b2008%5d.PDF (Accessed 25.01.18).
29.
OgawaY., & KanohS. (1984). Involvement of central action of lipopolysaccharide in pyrogen fever. Japanese Journal of Pharmacology36, 389–395.
MetzB., HendriksenC.F., JiskootW., & KerstenG.F. (2002). Reduction of animal use in human vaccine quality control: Opportunities and problems. Vaccine20, 2411–2430.
32.
NavegaE.C.A., SilvaC.C., PresgraveO.F., AlmeidaA.S., DelgadoI.F., & MattosK.A. (2015). Métodos alternativos ao uso de animais para a detecção de pirogênio: Oportunidades e desafios no controle da qualidade de produtos biológicos. Archives of Veterinary Science20, 71–81.
33.
Perdomo-MoralesR., Pardo-RuizZ., SpreitzerI., LagartoA., & MontagT. (2011). Monocyte activation test (MAT) reliably detects pyrogens in parenteral formulations of human serum albumin. ALTEX28, 227–235.
34.
SilvaC.C., PresgraveO.A., HartungT., de MoraesA.M., & DelgadoI.F. (2016). Applicability of the Monocyte Activation Test (MAT) for hyperimmune sera in the routine of the quality control laboratory: Comparison with the Rabbit Pyrogen Test (RPT). Toxicology in Vitro32, 70–75.
35.
GerkeC., ColucciA.M., GiannelliC., SanzoneS., VitaliC.G., SollaiL., RossiO., MartinL.B., AuerbachJ., Di CioccioV., & SaulA. (2015). Production of a Shigella sonnei vaccine based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB. PLoS One10, e0134478.
36.
StoddardM.B., PintoV., KeiserP.B., & ZollingerW. (2010). Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants. Clinical & Vaccine Immunology17, 98–107.
37.
VipondC., FindlayL., FeaversI., & CareR. (2016). Limitations of the rabbit pyrogen test for assessing meningococcal OMV based vaccines. ALTEX33, 47–53.
38.
KoryakinaA., FreyE., & BrueggerP. (2014). Cryopreservation of human monocytes for pharmacopeial monocyte activation test. Journal of Immunological Methods405, 181–191.
39.
PooleS., MistryY., BallC., Gaines DasR.E., OpieL.P., TuckerG., & PatelM. (2003). A rapid ‘one-plate’ in vitro test for pyrogens. Journal of Immunological Methods274, 209–220.
40.
LuheshiG., & RothwellN. (1996). Cytokines and fever. International Archives of Allergy & Immunology109, 301–307.
41.
BruunsgaardH., GalboH., Halkjaer-KristensenJ., JohansenT.L., MacLeanD.A., & PedersenB.K. (1997). Exercise-induced increase in serum inter-leukin-6 in humans is related to muscle damage. Journal of Physiology499, 833–841.
42.
CartmellT., PooleS., TurnbullA.V., RothwellN.J., & LuheshiG.N. (2000). Circulating inter-leukin-6 mediates the febrile response to localised inflammation in rats. Journal of Physiology526, 653–661.
43.
DinarelloC.A., GattiS., & BartfaiT. (1999). Fever: Links with an ancient receptor. Current Biology9, R147–R150.
44.
RockelC., & HartungT. (2012). Systematic review of membrane components of Gram-positive bacteria responsible as pyrogens for inducing human mono-cyte/macrophage cytokine release. Frontiers in Pharmacology3, 56.
45.
KimH., JungB.J., KimJ.Y., & ChungD.K. (2014). Differential effects of low and high doses of lipoteichoic acid on lipopolysaccharide-induced interleukin-6 production. Inflammation Research63, 419–428.
46.
Gaines DasR.E., BrüggerP., PatelM., MistryY., & PooleS. (2004). Monocyte activation test for pro-inflammatory and pyrogenic contaminants of parenteral drugs: Test design and data analysis. Journal of Immunological Methods288, 165–177.
